Current therapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome

International Journal of Hematology

Volumn 84, Issue 1, 2006, Pages 18-22

  Honda, Miwako ^a   Oka, Shinichi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Adherence; AIDS; HAART; Human immunodeficiency virus; Treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; INSULIN; LAMIVUDINE; LOPINAVIR; METFORMIN; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STATINE DERIVATIVE; STAVUDINE; SULFONYLUREA; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DIARRHEA; DRUG FATALITY; DRUG HYPERSENSITIVITY; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; HYPERLIPIDEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFLAMMATORY DISEASE; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIFE EXPECTANCY; LIPODYSTROPHY; LIVER TOXICITY; LOOSE FECES; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; REVIEW; VIRUS INHIBITION; VIRUS LOAD; VIRUS RESISTANCE; VOMITING; BLOOD; CHEMICALLY INDUCED DISORDER; METABOLIC DISORDER; METHODOLOGY; TIME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HUMANS; METABOLIC DISEASES; QUALITY OF LIFE; TIME FACTORS; VIRAL LOAD;

EID: 33748664832     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06102     Document Type: Review

References (29)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al, for the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection 2002: updated recommendations of the International AIDS Society - USA panel. JAMA. 2002;288:222-235.
3. + T-cell count. J Acquir Immune Defic Syndr. 2004;36:702-713.
4. Hammer SM, Squires KE, Hughes MD, et al, for the AIDS Clinical Trials Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
5. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 2001;286:2560-2567.
6. Hoggs RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.
7. Egger M, May M, Chene G, et al, and the ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
8. Ho DD. Time to hit HIV, early and hard. N Engl J Med. 1995;333:450-451.
9. Wood E, Hogg RS, Harrigan PR, Montaner JS. When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis. 2005;5:407-414.
10. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society - USA Panel. JAMA. 2004;292:251-265.
11. Weidle PJ, Ganea CE, Irwin KL, et al. Presence of human immunodeficiency virus (HIV) type 1, group M, non-B subtypes, Bronx, New York: a sentinel site for monitoring HIV genetic diversity in the United States. J Infect Dis. 2000;181:470-475.
12. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352:570-585.
13. Mandel GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Disease. 6th ed. New York, NY: Churchill Livingstone; 2005:1508.
14. US Dept of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents - October 6, 2005. Dept of Health and Human Services; 2005. AIDSinfo resources page. US Dept of Health and Human Services Web site. Available at: http://aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL10062005048.pdf. Accessed June 12, 2006.
15. BHIVA guidelines for the treatment of HIV-infected adults with antiretroviral therapy 2005. The British HIV Association Web site. Available at: http://www.bhiva.org/guidelines/2005/HIV/resistancetesting.html. Accessed June 13, 2006.
16. Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2004;39:609-629.
17. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
18. Walsh JC, Pozniak AL, Nelson MR, Mandalia S, Gazzard BG. Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J Acquir Immune Defic Syndr. 2002;30:278-287.
19. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357-366.
20. Gallego O, de Mendoza C, Perez-Elias MJ, et al. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS. 2001;15:1701-1706.
21. O'Brien ME, Clark RAL, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003;34:407-414.
22. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23:1603-1614.
23. Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS. 2005;19:979-981.
24. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62.
25. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS. 1999;13:2099-2013.
26. Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis. 2002;34:838-846.
27. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
28. Carr A, Samaras K, Thorisdottir A, Kaufman GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099.
29. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med. 2000;133:447-454.